Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial
The primary endpoint of the trial was defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE). Tradjenta had shown similar